Emergent forges five-year partnership to produce one billion doses of Janssen’s COVID-19 vaccine

pharmafile | July 7, 2020 | News story | Manufacturing and Production COVID-19, Emergent, J&J, JJ, Janssen, coronavirus 

As many pharma firms move to secure upscaled manufacturing capacity for their potential COVID-19 vaccines, Johnson & Johnson’s Janssen has done the same through a new deal with Emergent BioSolutions to manufacture the active pharmaceutical ingredients for the former’s adenovirus-based vaccine candidate for COVID-19.

This new agreement will last five years, the first two of which are valued at around $480 million, and follows the $135 million partnership forged between the two companies in April for drug substance manufacturing technology transfer services and capacity, with a goal of generating one billion doses – a target made in agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the US Government, which committed over $1 billion in funding for development and testing of Janssen’s vaccine candidate.

The work itself will take place at Emergent’s Baltimore Bayview facility, a site specially designed and established by the US Department of Health and Human Services (HHS), a designated Center for Innovation in Advanced Development and Manufacturing (CIAD) for the development and production of vaccines and interventions to combat public health emergencies. According to Emergent, the site has the capacity to manufacture anywhere from tens to hundreds of millions of doses of J&J’s vaccine candidate annually.

Robert G Kramer Sr, President and Chief Executive Officer of Emergent, remarked on the expanded partnership: “We are proud to deploy our manufacturing strength to address the COVID-19 pandemic. Advancing this collaboration is one of the ways we live our mission—to protect and enhance life.”

Matt Fellows

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …


Janssen submits sNDA to FDA for full approval of Balversa

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …

FDA approved Janssen’s Akeega for prostate cancer treatment

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and …

Latest content